AUA 2017: AUA Guideline 2017: Stress Urinary Incontinence

Boston, MA ( This is the 3rd AUA guideline on stress UI (SUI).  AUA felt that continual updates are needed as surgical options are evolving.  Dr Kobashi reviewed the methodology. 

AUA 2017: Long-term combination treatment with solifenacin and mirabegron is effective and well-tolerated in patients with overactive bladder

Boston, MA ( randomized controlled trial parallel group, active-controlled multicenter study to evaluate the safety of long-term combination treatment of solifenacin 5 mg (Soli) and mirabegron 50 mg (Mira) compared with each monotherapy.

AUA 2017: Specific changes in brain activity in women with overactive bladder after successful sacral neuromodulation with Interstim: An fMRI study.

Boston, MA ( The study aim was to measure changes in brain activity associated with sacral neuromodulation (SNS) treatment of OAB.  It was hypothesized that SNS treatment with attenuate pre-existing areas of increased brain activity. 

AUA 2017: Association between urinary symptom severity and automated segmentation of white matter plaque in women with multiple sclerosis.

Boston, MA ( Multiple sclerosis (MS) is characterized by demyelinated white matter plaque throughout the central nervous system. Patients with MS frequently experience a range of bothersome urinary symptoms.

AUA 2017: Is a Group Learning Behavioral Modification Program Effective and Safe in Reducing Geriatric Urinary Incontinence? A Multi-Center Randomized Controlled Trial

Boston, MA ( This was a multi-center randomized controlled trial of women > 55 yrs who had stress, urgency or mixed urinary incontinence (UI) for at least 3 months and a reported ICIQ-UI SF score of 3 or more (1 or more score for leakage frequency, 2 or more score for volume loss).  Study objective was to establish the effectiveness & safety of a Group-administered Behavioral Treatment (GBT) by comparing it to no treatment.